Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Oncology · Pancreatic Neuroendocrine Tumor

Standard of Care Treatment Options

At a Glance

Treatment for pancreatic neuroendocrine tumors (pNETs) ranges from active surveillance for small, slow-growing tumors to surgical removal. Advanced options include hormone-blocking medications, oral chemotherapy (CAPTEM), and targeted radiation therapy like PRRT (Lutathera).

Once the specific characteristics of your pancreatic neuroendocrine tumor (pNET) are understood, you and your care team will decide on a management strategy. Because pNETs are so varied and complex, your case should ideally be reviewed by a Multidisciplinary Tumor Board—a team of specialized surgeons, oncologists, and endocrinologists who collaborate to build the best plan for you [1][2].

Monitoring vs. Surgery

For many cancers, immediate surgery is the only thought. However, with pNETs, a more conservative approach is sometimes the safest path:

  • Active Surveillance: If your tumor is non-functional (not producing hormones), small (typically ≤2 cm), and slow-growing (Grade 1), your doctor may recommend “watchful waiting” or active surveillance [3][4]. This involves regular scans to ensure the tumor isn’t growing. Research shows that for these small tumors, long-term outcomes for surveillance can be comparable to surgery, while avoiding the risks and long recovery times of a major operation [3][5].
  • Surgical Resection: Surgery remains the primary treatment for larger tumors or those causing symptoms [6]. The specific procedure depends on the tumor’s location:
    • Whipple Procedure (Pancreaticoduodenectomy): Used for tumors in the “head” of the pancreas [7].
    • Distal Pancreatectomy: Used for tumors in the “body” or “tail” of the pancreas [7].
    • Enucleation: A smaller surgery that carefully “scoops out” small, well-defined tumors to preserve as much healthy pancreas as possible [8][9].

Medical Therapies

When a tumor is producing hormones or growing too quickly for surveillance, several non-surgical options are available:

  • Somatostatin Analogs (SSAs): Drugs like octreotide and lanreotide are often the first line of defense. They mimic a natural hormone that binds to receptors on the tumor, stopping hormone overproduction and physically slowing tumor growth [10][11]. Side effects to expect: Potential for gallstones, and oily stools or diarrhea due to reduced digestive enzymes [12].
  • Targeted Therapies: Daily pills like everolimus and sunitinib “target” the specific pathways tumors use to grow and build blood vessels [13][10]. Side effects to expect: Can cause mouth sores, fatigue, or changes in blood sugar and blood pressure [14].
  • Chemotherapy (CAPTEM): While pNET patients do not typically receive the aggressive IV chemotherapy used for standard pancreatic cancer, oral chemotherapy is highly effective for neuroendocrine tumors. The most common regimen is CAPTEM (a combination of capecitabine and temozolomide pills). It is particularly useful for shrinking larger tumors or treating tumors that are growing quickly [15][16]. Side effects to expect: Nausea, fatigue, and lowered blood cell counts [15].

Precision Nuclear Medicine: PRRT

Peptide Receptor Radionuclide Therapy (PRRT), specifically with a drug called 177Lu-DOTATATE (Lutathera), is a highly targeted form of treatment for advanced pNETs [17].

This therapy works like a “smart bomb.” It uses a somatostatin analog to find the receptors on the tumor cells—just like the tracer used in your PET scan [17][18]. Attached to this analog is a radioactive isotope (Lutetium-177) that delivers a concentrated dose of radiation directly to the tumor cells, damaging their DNA [17][19]. To be eligible for PRRT, your previous DOTATATE PET scan must show that your tumor has enough of these receptors to “catch” the treatment [20]. Side effects to expect: Fatigue, mild nausea, and temporary drops in blood cell counts (myelosuppression) [21].

Every treatment plan is a balance between controlling the disease and maintaining your quality of life. Your grade, symptoms, and scan results will guide which of these tools is right for your situation [22].

Common questions in this guide

Is surgery always required for a pancreatic neuroendocrine tumor?
Not always. For small, slow-growing tumors that do not produce hormones, doctors may recommend active surveillance. This involves regular monitoring with scans to avoid the risks of a major surgery unless the tumor begins to grow.
What surgical procedures are used to remove pNETs?
The type of surgery depends on the tumor's location. Options include the Whipple procedure for tumors in the head of the pancreas, a distal pancreatectomy for the body or tail, or an enucleation procedure that scoops out small tumors to preserve healthy tissue.
What are somatostatin analogs (SSAs) and how do they work?
Somatostatin analogs, like octreotide or lanreotide, are medications that mimic a natural hormone. They bind to tumor receptors to stop the overproduction of hormones and can also physically slow the growth of the tumor.
How is chemotherapy used to treat pNETs?
Unlike aggressive intravenous chemotherapy used for other cancers, pNETs are often treated with highly effective oral chemotherapy pills. A common combination called CAPTEM (capecitabine and temozolomide) is used to shrink larger or fast-growing tumors.
Am I a candidate for PRRT (Lutathera)?
Peptide Receptor Radionuclide Therapy (PRRT) is a targeted treatment that delivers radiation directly into tumor cells. To be eligible, you must first have a DOTATATE PET scan to confirm your tumor has the specific receptors needed to absorb the medication.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my tumor small and slow-growing enough to consider active surveillance instead of surgery?
  2. 2.If surgery is recommended, would I be receiving a Whipple procedure, a distal pancreatectomy, or an enucleation?
  3. 3.Are somatostatin analogs like octreotide or lanreotide appropriate for my tumor grade and hormone status?
  4. 4.If chemotherapy is suggested, are we considering oral CAPTEM, and how does it differ from traditional IV chemo?
  5. 5.Am I a candidate for PRRT (Lutathera), and what does my PET scan tell us about its potential effectiveness?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Interpretable deep learning model and nomogram for predicting pathological grading of PNETs based on endoscopic ultrasound.

    Mo S, Zhang Y, Liu N, et al.

    BMC medical informatics and decision making 2025; (25(1)):360 doi:10.1186/s12911-025-03193-3.

    PMID: 41039509
  2. 2

    Surgical management of pancreatic neuroendocrine tumors: an introduction.

    Hain E, Sindayigaya R, Fawaz J, et al.

    Expert review of anticancer therapy 2019; (19(12)):1089-1100 doi:10.1080/14737140.2019.1703677.

    PMID: 31825691
  3. 3

    The management of small nonfunctional pancreatic neuroendocrine tumors: It's time to define the high-risk features.

    Tan Q, Chengzhi X, Chen Y

    Journal of surgical oncology 2022; (126(6)):1135-1136 doi:10.1002/jso.27025.

    PMID: 36004442
  4. 4

    Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA).

    Heidsma CM, Engelsman AF, van Dieren S, et al.

    The British journal of surgery 2021; (108(8)):888-891 doi:10.1093/bjs/znab088.

    PMID: 33783475
  5. 5

    Management of MEN1 Related Nonfunctioning Pancreatic NETs: A Shifting Paradigm: Results From the DutchMEN1 Study Group.

    Nell S, Verkooijen HM, Pieterman CRC, et al.

    Annals of surgery 2018; (267(6)):1155-1160 doi:10.1097/SLA.0000000000002183.

    PMID: 28257328
  6. 6

    Surgical Management of Pancreatic Neuroendocrine Tumors.

    Clancy TE

    Hematology/oncology clinics of North America 2016; (30(1)):103-18.

    PMID: 26614371
  7. 7

    Surgical Versus Nonsurgical Management of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.

    Khajeh E, Shahrbaf M, Apostolidis L, et al.

    Annals of surgical oncology 2025; (32(10)):7532-7549 doi:10.1245/s10434-025-17819-3.

    PMID: 40705264
  8. 8

    [Enucleation of pancreatic tumors: a multiple-center study].

    Solodkiy VA, Kriger AG, Akhaladze GG, et al.

    Khirurgiia 2023; 13-20 doi:10.17116/hirurgia202302113.

    PMID: 36748866
  9. 9

    Comparison of clinical outcomes between enucleation and regular pancreatectomy in patients with non-functional pancreatic neuroendocrine tumors: a retrospective multicenter and propensity score-matched study.

    Yang Z, Gao H, Lu J, et al.

    Japanese journal of clinical oncology 2021; (51(4)):595-603 doi:10.1093/jjco/hyaa246.

    PMID: 33395471
  10. 10

    Systemic therapy in incurable gastroenteropancreatic neuroendocrine tumours: a clinical practice guideline.

    Singh S, Sivajohanathan D, Asmis T, et al.

    Current oncology (Toronto, Ont.) 2017; (24(4)):249-255 doi:10.3747/co.24.3634.

    PMID: 28874893
  11. 11

    Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.

    Pokuri VK, Fong MK, Iyer R

    Current oncology reports 2016; (18(1)):7 doi:10.1007/s11912-015-0492-7.

    PMID: 26743514
  12. 12

    Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.

    Stueven AK, Kayser A, Wetz C, et al.

    International journal of molecular sciences 2019; (20(12)) doi:10.3390/ijms20123049.

    PMID: 31234481
  13. 13

    The Molecular and Clinical Landscape of Pancreatic Neuroendocrine Tumors.

    Batukbhai BDO, De Jesus-Acosta A

    Pancreas 2019; (48(1)):9-21 doi:10.1097/MPA.0000000000001189.

    PMID: 30531241
  14. 14

    177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.

    Satapathy S, Mittal BR

    Nuclear medicine communications 2019; (40(12)):1195-1203 doi:10.1097/MNM.0000000000001103.

    PMID: 31658219
  15. 15

    Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity.

    Clewemar Antonodimitrakis P, Sundin A, Wassberg C, et al.

    Neuroendocrinology 2016; (103(3-4)):345-53 doi:10.1159/000439086.

    PMID: 26279284
  16. 16

    Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023.

    di Santo G, Santo G, Sviridenko A, Virgolini I

    Theranostics 2024; (14(3)):940-953 doi:10.7150/thno.91268.

    PMID: 38250038
  17. 17

    Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy.

    Hennrich U, Kopka K

    Pharmaceuticals (Basel, Switzerland) 2019; (12(3)) doi:10.3390/ph12030114.

    PMID: 31362406
  18. 18

    Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy.

    O'Neill E, Kersemans V, Allen PD, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2020; (61(5)):743-750 doi:10.2967/jnumed.119.232934.

    PMID: 31757844
  19. 19

    177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.

    Demirci E, Kabasakal L, Toklu T, et al.

    Nuclear medicine communications 2018; (39(8)):789-796 doi:10.1097/MNM.0000000000000874.

    PMID: 29912750
  20. 20

    ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.

    Love C, Desai NB, Abraham T, et al.

    American journal of clinical oncology 2022; (45(6)):233-242 doi:10.1097/COC.0000000000000903.

    PMID: 35507413
  21. 21

    Overview and Current Status of Peptide Receptor Radionuclide Therapy.

    Bushnell DL, Bodeker KL

    Surgical oncology clinics of North America 2020; (29(2)):317-326 doi:10.1016/j.soc.2019.11.005.

    PMID: 32151363
  22. 22

    Evaluation and Management of Neuroendocrine Tumors of the Pancreas.

    Scott AT, Howe JR

    The Surgical clinics of North America 2019; (99(4)):793-814 doi:10.1016/j.suc.2019.04.014.

    PMID: 31255207

This page provides educational information about standard treatments for pancreatic neuroendocrine tumors (pNETs). It does not replace professional medical advice; please discuss your specific treatment options with your multidisciplinary tumor board.

Get notified when new evidence is published on Neuroendocrine tumor of pancreas.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.